About Dova pharmaceuticals
Dova Pharmaceuticals: Delivering Innovative Therapies to Improve the Lives of Rare Disease Patients
Dova Pharmaceuticals is a biopharmaceutical company that is committed to developing and delivering innovative therapies to improve the lives of rare disease patients. The company was founded in 2016 and has since been focused on developing treatments for thrombocytopenia, a condition characterized by low platelet counts.
The company's lead product, DOPTELET® (avatrombopag), was approved by the U.S. Food and Drug Administration (FDA) in May 2018 for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. DOPTELET® is an oral thrombopoietin receptor agonist that stimulates the production of platelets, which are essential for blood clotting.
In addition to DOPTELET®, Dova Pharmaceuticals has several other products in its pipeline that are aimed at addressing unmet medical needs in rare diseases. These include:
- A drug candidate for the treatment of chemotherapy-induced thrombocytopenia
- A drug candidate for the treatment of idiopathic thrombocytopenic purpura (ITP)
- A drug candidate for the treatment of acute myeloid leukemia (AML)
The company's mission is driven by its commitment to improving patient outcomes through innovation and collaboration with healthcare providers, patient advocacy groups, and regulatory agencies.
Dova Pharmaceuticals' team consists of experienced professionals with diverse backgrounds in pharmaceuticals, biotechnology, clinical research, regulatory affairs, and commercialization. The team's expertise enables them to navigate complex regulatory environments while maintaining a focus on patient needs.
The company's culture emphasizes transparency, accountability, integrity, and respect. These values guide all aspects of their operations from research and development through commercialization.
Dova Pharmaceuticals' commitment to innovation extends beyond its product pipeline. The company also invests heavily in research collaborations with academic institutions and other industry partners. These collaborations enable them to leverage cutting-edge technologies while expanding their knowledge base across multiple therapeutic areas.
In conclusion,
Dova Pharmaceuticals is dedicated to improving patient outcomes through innovative therapies that address unmet medical needs in rare diseases such as thrombocytopenia. With an experienced team guided by strong values such as transparency and integrity coupled with strategic partnerships across academia & industry; they continue pushing boundaries towards better health care solutions every day!
dova.com
